Singapore, May 20 -- RevolKa Ltd., a venture-backed biotech company providing a cutting-edge artificial intelligence (AI)-driven protein engineering technology platform calledaiProtein(R), has raised $1.4 million in Series A extension funding.

This funding will advance RevolKa's drug discovery programmes for rare diseases and support collaborative partnering efforts. This financing round was co-led by existing investors, D3 LLC (Tomoya Nagata, Managing Partner, CEO) and TOHOKU University Venture Partners Co. with participation from DEEPCORE Inc.RevolKa's core technology,aiProteinis a robust AI-driven protein engineering technology that creates exceptionally high-performance proteins. This technology platform has already produced many suc...